Single-Dose Netupitant/Palonosetron Bests 3-Day Aprepitant-Based Regimen to Prevent CINV

August 02, 2020

A single-dose combination of netupitant/palonosetron demonstrated better efficacy compared with a 3-day aprepitant-based regimen, according to results of a pooled analysis of multiple phase 2/3 studies investigating the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

FDA Approves Tafasitamab/Lenalidomide for R/R DLBCL

August 01, 2020

The FDA has approved tafasitamab-cxix in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specific, including DLBCL arising from low-grade lymphoma, and patients who are not eligible for autologous stem cell transplant.

Recommendations for Managing Patients With Lung Cancer During COVID-19 Era

July 31, 2020

In response to the COVID-19 pandemic, the European Society of Medical Oncology has published recommendations for the management of patients with lung cancer to maintain high-quality standards of treatment.

Trending News on Targeted Oncology, Week of July 31, 2020

July 31, 2020

Targeted Oncology reviews trending news online for the week of July 31, 2020, including recent news from the FDA, updates in oncology, and new information regarding COVID-19.

A Look Back at the FDA News from July 2020

July 31, 2020

Here is a look back at the FDA happenings from the month of July 2020.

Axi-Cel Retains Its Benefit in a Real-World Setting in Large B-Cell Lymphomas

July 31, 2020

Axicabtagene ciloleucel demonstrated a similar overall response rate in both the trial and non-trial settings as treatment of patients with relapsed or refractory large B-cell lymphoma.

Treatment Landscape for Acute Myeloid Leukemia Appears Hopeful for Patients

July 31, 2020

Eunice Wang, MD, discusses the excitement she has experienced in the treatment landscape of acute myeloid leukemia over the last several years due to the number of new treatment options approved by the FDA.

Targeted Therapy in Early-Stage HER2+ Breast Cancer

July 31, 2020

Experts from Sarah Cannon Research Institute talk about the expanding role of targeted treatment options in early HER2+ breast cancer.

FDA Approves Atezolizumab Triplet Regimen for Treatment of Advanced BRAF-Mutant Melanoma

July 30, 2020

The FDA granted approval to atezolizumab in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600E-mutated advanced melanoma.

FDA Approval Being Considered for Neoadjuvant/Adjuvant Pembrolizumab +/- Chemo in Early TNBC

July 30, 2020

The FDA has accepted a supplemental Biologics License Application submitted for neoadjuvant pembrolizumab combined with chemotherapy and adjuvant pembrolizumab monotherapy for the treatment of patients with high-risk early-stage triple-negative breast cancer.

Pembrolizumab Plus Chemotherapy on the Road to FDA Approval for mTNBC, Granted Priority Review

July 30, 2020

The FDA accepted a supplemental Biologics License Application for and granted Priority Review to pembrolizumab in combination with chemotherapy, which is intended for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1.

Clinical Trials Remain Underway for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

July 30, 2020

Ian E. Krop, MD, PhD, discusses the importance of clinical trials further exploring the role of trastuzumab deruxtecan following the FDA’s approval of the agent as treatment of patients with HER2-positive metastatic breast cancer.